Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

bimekizumab-bkzx

- PMLiVE

UCB presentation highlights impacts of epilepsy on daily life

The data underlines the consequences of disrupted sleep for patients and caregivers

- PMLiVE

J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE

UCB’s Kygevvi receives positive CHMP opinion for thymidine kinase 2 deficiency

TK2d is an extremely rare disease characterised by severe and progressive muscle weakness

- PMLiVE

UCB releases new data on Bimzelx for hidradenitis suppurativa

The disease affects around 1% of the population in most studied countries

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

UCB shares promising results for fenfluramine in ultra-rare form of epilepsy

CDKL5 deficiency disorder occurs in approximately one in 40,000 to 60,000 live births

- PMLiVE

UCB’s Bimzelx demonstrates lasting efficacy in phase 3 psoriatic arthritis trials

Approximately 125 million people worldwide are affected by some form of psoriasis

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

An estimated eight million people in the US are living with the immune-mediated skin disease

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis programme

More than 125 million people worldwide are estimated to be living with the immune-mediated skin disease

- PMLiVE

Bristol Myers Squibb shares five-year results for Sotyktu in plaque psoriasis

Plaque psoriasis affects up to 90% of patients with the immune-mediated disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links